• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Adagene Inc.

    2/17/26 4:30:25 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADAG alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Adagene Inc.

    (Name of Issuer)


    Ordinary shares, par value US$0.0001 per share

    (Title of Class of Securities)


    005329107

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    General Atlantic Singapore Fund Pte. Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    SINGAPORE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    General Atlantic Singapore Interholdco Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    General Atlantic Partners (Bermuda) IV, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    General Atlantic Partners (Bermuda) EU, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    General Atlantic GenPar (Bermuda), L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    GAP (Bermuda) L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    GENERAL ATLANTIC, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    GAP Coinvestments III, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    GAP Coinvestments IV, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    GAP Coinvestments V, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    GAP Coinvestments CDA, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    General Atlantic Partners (Lux) SCSp
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    LUXEMBOURG
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    General Atlantic GenPar (Lux) SCSp
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    LUXEMBOURG
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    General Atlantic (Lux) S.a r.l.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    LUXEMBOURG
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    General Atlantic Singapore AI Pte. Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    SINGAPORE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Adagene Inc.
    (b)Address of issuer's principal executive offices:

    4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, 215123, People's Republic of China
    Item 2. 
    (a)Name of person filing:

    This statement is being filed on behalf of each of the following persons (collectively, the "Reporting Persons"). (i) General Atlantic Singapore Fund Pte. Ltd. ("GASF"); (ii) General Atlantic Singapore Interholdco Ltd. ("GAS Interholdco"); (iii) General Atlantic Partners (Bermuda) IV, L.P. ("GAP Bermuda IV"); (iv) General Atlantic Partners (Bermuda) EU, L.P. ("GAP Bermuda EU"); (v) General Atlantic GenPar (Bermuda), L.P. ("GenPar Bermuda"); (vi) GAP (Bermuda) L.P. ("GAP (Bermuda) LP"); (vii) General Atlantic, L.P. ("GA LP"); (viii) GAP Coinvestments III, LLC ("GAPCO III"); (ix) GAP Coinvestments IV, LLC ("GAPCO IV"); (x) GAP Coinvestments V, LLC ("GAPCO V"); (xi) GAP Coinvestments CDA, L.P. ("GAPCO CDA"); (xii) General Atlantic Partners (Lux) SCSp ("GAP Lux"); (xiii) General Atlantic GenPar, (Lux) SCSp ("GA GenPar Lux"); (xiv) General Atlantic (Lux) S.a. r.l. ("GA Lux"); and (xv) General Atlantic Singapore AI Pte. Ltd. ("GA AI"). GAP Bermuda IV, GAP Bermuda EU, GAP Lux, GAPCO III, GAPCO IV, GAPCO V and GAPCO CDA are collectively referred to as the "GA Funds." The CUSIP appearing on the cover page of this statement applies to the American Depositary Shares (the "ADSs"), evidenced by American Depositary Receipts, each representing one and one quarter (1.25) ordinary shares. No CUSIP has been assigned to the ordinary shares.
    (b)Address or principal business office or, if none, residence:

    The address of GA LP, GAPCO III, GAPCO IV, GAPCO V, and GAPCO CDA is c/o General Atlantic Service Company, L.P., 55 East 52nd Street, 33rd Floor, New York, NY 10055. The address of GAS Interholdco, GAP Bermuda IV, GAP Bermuda EU, GenPar Bermuda, and GAP (Bermuda) LP is C/O Conyers Client Services Limited, Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. The address of GAP Lux, GA GenPar Lux and GA Lux Sarl is 412F, route d'Esch, L-2086 Luxembourg, Grand Duchy of Luxembourg. The address of GASF and GA AI is 80 Robinson Road #02-00, Singapore, 068898.
    (c)Citizenship:

    (i) GASF - Singapore (ii) GAS Interholdco - Bermuda (iii) GAP Bermuda IV - Bermuda (iv) GAP Bermuda EU - Bermuda (v) GenPar Bermuda - Bermuda (vi) GAP (Bermuda) LP - Bermuda (vii) GA LLC - Delaware (viii) GAPCO III - Delaware (ix) GAPCO IV - Delaware (x) GAPCO V - Delaware (xi) GAPCO CDA - Delaware (xii) GAP Lux - Luxembourg (xiii) GA GenPar Lux - Luxembourg (xiv) GA Lux - Luxembourg (xv) GA AI - Singapore
    (d)Title of class of securities:

    Ordinary shares, par value US$0.0001 per share
    (e)CUSIP No.:

    005329107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of December 31, 2025, none of the Reporting Persons beneficially owned any ADSs or ordinary shares. GA AI is wholly owned by GASF. The majority shareholder of GASF is GAS Interholdco. The members of GAS Interholdco that share beneficial ownership of the ADSs held of record by GA AI are the GA Funds. The general partner of GAP Lux is GA GenPar Lux and the general partner of GA GenPar Lux is GA Lux. The general partner of GAP Bermuda EU and GAP Bermuda IV and the sole shareholder of GA Lux is GenPar Bermuda. GAP (Bermuda) LP, which is controlled by the Management Committee of GASC MGP, LLC (the "GA Management Committee"), is the general partner of GenPar Bermuda. GA LP, which is also controlled by the GA Management Committee, is the managing member of GAPCO III, GAPCO IV and GAPCO V and the general partner of GAPCO CDA. There are six members of the GA Partnership Committee as of the date hereof. Each of the members of the GA Partnership Committee disclaims ownership of the ADSs and the underlying ordinary shares except to the extent that he has a pecuniary interest therein. The name, the business address and the citizenship of each of the members of the GA Partnership Committee and the directors of GASF and GAS Interholdco, in each case as of the date hereof, is attached hereto as Schedule A and is hereby incorporated by reference. Amount Beneficially Owned: By virtue of the relationship described above, each of the Reporting Persons may be deemed to beneficially own 0 ADSs representing 0 ordinary shares.
    (b)Percent of class:

    Percentage Owned: All calculations of percentage ownership herein are based on an aggregate of 58,914,087 ordinary shares of the Issuer reported to be outstanding as of June 30, 2025, as reflected in the Issuer's Prospectus, filed with the U.S. Securities and Exchange Commission on January 9, 2026.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Each of the Reporting Persons may be deemed to have the sole power to direct the voting and dispositions of the ordinary shares, the ADSs and underlying ordinary shares as indicated on such Reporting Person's cover page included herein.

     (ii) Shared power to vote or to direct the vote:

    Each of the Reporting Persons may be deemed to share the power to direct the voting and dispositions of 0 ADSs representing 0 ordinary shares that may be deemed to be owned beneficially by each of them.

     (iii) Sole power to dispose or to direct the disposition of:

    Each of the Reporting Persons may be deemed to share the power to direct the voting and dispositions of 0 ADSs representing 0 ordinary shares that may be deemed to be owned beneficially by each of them.

     (iv) Shared power to dispose or to direct the disposition of:

    Each of the Reporting Persons may be deemed to share the power to direct the voting and dispositions of 0 ADSs representing 0 ordinary shares that may be deemed to be owned beneficially by each of them.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Item 4, which states the identity of the members of the group filing this Schedule 13G.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    General Atlantic Singapore Fund Pte. Ltd.
     
    Signature:/s/ Ong Yu Huat
    Name/Title:Ong Yu Huat, Director
    Date:02/17/2026
     
    General Atlantic Singapore Interholdco Ltd.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Director
    Date:02/17/2026
     
    General Atlantic Partners (Bermuda) IV, L.P.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of GAP (BERMUDA) GP LTD, the general partner of GAP (BERMUDA) L.P., the general partner of GENERAL ATLANTIC GENPAR, LP
    Date:02/17/2026
     
    General Atlantic Partners (Bermuda) EU, L.P.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of GAP (BERMUDA) GP LTD, the general partner of GAP (BERMUDA) L.P., the general partner of GENERAL ATLANTIC GENPAR, LP
    Date:02/17/2026
     
    General Atlantic GenPar (Bermuda), L.P.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of GAP (BERMUDA) GP LIMITED, the general partner of GAP (BERMUDA) L.P., its general partner
    Date:02/17/2026
     
    GAP (Bermuda) L.P.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of GAP (BERMUDA) GP LIMITED, its general partner
    Date:02/17/2026
     
    GENERAL ATLANTIC, L.P.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director
    Date:02/17/2026
     
    GAP Coinvestments III, LLC
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of GENERAL ATLANTIC, L.P., its managing member
    Date:02/17/2026
     
    GAP Coinvestments IV, LLC
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of GENERAL ATLANTIC, L.P., its managing member
    Date:02/17/2026
     
    GAP Coinvestments V, LLC
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of GENERAL ATLANTIC, L.P., its managing member
    Date:02/17/2026
     
    GAP Coinvestments CDA, L.P.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of GENERAL ATLANTIC, L.P., its general partner
    Date:02/17/2026
     
    General Atlantic Partners (Lux) SCSp
     
    Signature:/s/ Ingrid van der Hoorn
    Name/Title:Ingrid van der Hoorn, Manager A of GENERAL ATLANTIC (LUX) S.A R.L., the general partner of GENERAL ATLANTIC GENPAR (LUX) SCSP, its general partner
    Date:02/17/2026
     
    Signature:/s/ William Blackwell
    Name/Title:William Blackwell, Manager B of GENERAL ATLANTIC (LUX) S.A R.L., the general partner of GENERAL ATLANTIC GENPAR (LUX) SCSP, its general partner
    Date:02/17/2026
     
    General Atlantic GenPar (Lux) SCSp
     
    Signature:/s/ Ingrid van der Hoorn
    Name/Title:Ingrid van der Hoorn, Manager A of General Atlantic (Lux) S.a.r.l., its general partner
    Date:02/17/2026
     
    Signature:/s/ William Blackwell
    Name/Title:William Blackwell, Manager B of General Atlantic (Lux) S.a.r.l., its general partner
    Date:02/17/2026
     
    General Atlantic (Lux) S.a r.l.
     
    Signature:/s/ Ingrid van der Hoorn
    Name/Title:Ingrid van der Hoorn, Manager A
    Date:02/17/2026
     
    Signature:/s/ William Blackwell
    Name/Title:William Blackwell, Manager B
    Date:02/17/2026
     
    General Atlantic Singapore AI Pte. Ltd.
     
    Signature:/s/ Ong Yu Huat
    Name/Title:Ong Yu Huat, Director
    Date:02/17/2026
    Exhibit Information

    Exhibit 1: Agreement relating to the filing of joint acquisition statements as required by Rule 13d-1(k)(1) under the Act (previously filed). (https://www.sec.gov/Archives/edgar/data/1017645/000095014222000609/eh220223350_13g-adagene.htm)

    Get the next $ADAG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAG

    DatePrice TargetRatingAnalyst
    11/24/2025$9.00Buy
    Guggenheim
    8/6/2025$7.00Outperform
    Leerink Partners
    1/31/2025Overweight → Equal-Weight
    Morgan Stanley
    2/1/2022$27.00 → $15.00Overweight
    Morgan Stanley
    More analyst ratings

    $ADAG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Adagene with a new price target

    Guggenheim initiated coverage of Adagene with a rating of Buy and set a new price target of $9.00

    11/24/25 8:15:55 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Adagene with a new price target

    Leerink Partners initiated coverage of Adagene with a rating of Outperform and set a new price target of $7.00

    8/6/25 7:24:59 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene downgraded by Morgan Stanley

    Morgan Stanley downgraded Adagene from Overweight to Equal-Weight

    1/31/25 8:29:36 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Adagene Inc.

    SCHEDULE 13G/A - Adagene Inc. (0001818838) (Subject)

    2/17/26 4:30:25 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Adagene Inc.

    SCHEDULE 13G/A - Adagene Inc. (0001818838) (Subject)

    1/29/26 4:16:34 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Adagene Inc.

    6-K - Adagene Inc. (0001818838) (Filer)

    1/23/26 8:00:14 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adagene to Participate in Two Upcoming Investor Conferences

    SAN DIEGO and SUZHOU, China, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held virtually on February 25, 2026 and the Leerink Global Healthcare Conference being held March 8-11, 2026 in Miami, Florida. Oppenheimer 36th Annual Healthcare Life Sciences Conference (Virtual) Format: Fireside chatDate/Time: Wednesday, February 25, 2026 at 4:00 PM (East

    2/17/26 9:27:16 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene Provides Business Update and 2026 Objectives

    Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026 Unaudited cash and cash equivalents of $74.5 million as of December 31, 2025 anticipated to provide sufficient runway into late 2027 SAN DIEGO and SUZHOU, China, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced year-end unaudited cash and cash equivalents of $74.5 million and provided a business update. 2025 Key Accomplishments: Phase 1b/2 trial results with muzastotug in MSS CRC at ASCO: Shared updated data from 10 mg/kg and 20 mg/

    1/23/26 8:00:00 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

    Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated muzastotug, in combination with Merck's (known as MSD outside of the United States and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as a Fast Track product for adult patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) without current or active liver metastases. Muzas

    12/16/25 7:00:00 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    Financials

    Live finance-specific insights

    View All

    Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

    – Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be presented at SITC 2022 – – Masked, anti-CTLA-4 antibody, ADG126, safely dosed repeatedly up to 20 mg/kg as a single agent with encouraging efficacy signals; results to be presented at ESMO 2022 – – Presentation of combination dosing data with anti-PD-1 therapies in 2022, while dose expansion begins for both ADG116 and ADG126 in targeted tumors – – Submitted regulatory filing for clinical trial of masked, IgG1-based anti-CD137 candidate, ADG206, with greater preclinical potency than the analog of

    8/30/22 5:25:00 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Adagene Inc.

    SC 13G/A - Adagene Inc. (0001818838) (Subject)

    11/7/24 4:32:13 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Adagene Inc. (Amendment)

    SC 13D/A - Adagene Inc. (0001818838) (Subject)

    3/1/24 4:30:20 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Adagene Inc. (Amendment)

    SC 13G/A - Adagene Inc. (0001818838) (Subject)

    2/9/24 8:35:54 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    Leadership Updates

    Live Leadership Updates

    View All

    Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

    SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor. "Adagene is advancing the field of Immuno-Oncology with its pipeline of innovative antibodies centered around CTLA-4, a master-regulator of T-cell responses. This includes ADG116 to differentially engage CTLA-4 for greater T-reg depletion, and ADG126 to mask the CTLA-4 binder (ADG116) until it reaches the tumor microenvironment aiming for an enhanced efficacy and reduced toxicity profile. The design of these antibodies may allow a broad

    9/3/25 9:05:21 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

    - Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. "Adagene is currently breaking a toxicity barrier with their proprietary masking technology, delivering a checkpoint inhibitor selectively and conditionally to tumor cells. Their platform has broad potential for enhanced immunotherapy with effective regulatory T-cell depletion, in conjunction with monoclonal antibodies, bispecifics, T-cell engagers, and antibod

    4/28/25 8:00:00 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

    - Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy - SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the "SAB"). Dr. Lenz is the Associate Director for Clinical Research and Co-leader of the Translational Science Program at the USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC and Co-Director of the Center for Cancer Drug Development a

    3/7/24 4:01:00 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care